EMEA accepts filing of Schering-Plough's fertility treatment
This article was originally published in Scrip
Executive Summary
Schering-Plough's marketing authorisation application for its single-injection, sustained follicle stimulant, corifollitropin alfa, has been accepted for review by the EMEA.